Canaccord Genuity analyst Jason Mills maintains TransMedics Gr (NASDAQ:TMDX) with a Buy and raises the price target from $102 to $117.
Canaccord Genuity Maintains Buy on TransMedics Gr, Raises Price Target to $117
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.